Durham, N.C. — The successful Phase III clinical trial of a dry-eye drug in Japan has earned Inspire Pharmaceuticals (Nasdaq: ISPH) a $1.25 million milestone payment.
Santen Pharmaceuticals licensed Inspire’s “diquafosol” and is planning to seek marketing approval to sell the drug in June.
Santen also has license, development and supply agreements for the drug in China, South Korea, Singapore and other Asian markets.
Related Items
On The Web
Related Topics
- Pharmaceuticals Sector
- Health and Human Services Sector
- Biotechnology Sector
- Technology
- Science and Technology
- Medicine
- Medical Technology
- Health and Fitness
- Financial Markets
- Clinical Trials
![[search]](http://wwwcache.wral.com/presentation/v1/images/icons/16x12/search-form-icon.gif)
Site Search
Inspire Pharmaceuticals Receives $1.25M Milestone Payment
Copyright 2008 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
News Alerts to your Email & Cell Phone-
- U.S. philanthropic funders face the downturn
Posted -33280 minutes ago - Hinting at a Cisco deal, analyst changes course, says Red Hat a 'buy'
Updated Dec. 4 6:31 p.m. - Sencera hits solar panel benchmark, lands $5.2M in additional funding
Posted Dec. 4 1:55 p.m. - Clinical research firm PRA International opens third German office
Posted Dec. 4 1:39 p.m. - Durham-based Parion receives $5M from Gilead Sciences
Posted Dec. 4 1:04 p.m.
- U.S. philanthropic funders face the downturn
-
- Atlanta-based social media startup ThePort lands $4.1M in new funding
Posted Dec. 4 11:20 a.m. - Triangle-based Integrian is sold; CEO leaves; some 30 people laid off
Updated Dec. 4 12:12 p.m. - European tech investors take a stake in e-mail marketing firm Silverpop
Dec. 3, 2008 - Interested in ‘crowdsourcing’? Check out UTest
Dec. 3, 2008 - Atlanta startup Band Metrics lands angel funding
Dec. 3, 2008
- Atlanta-based social media startup ThePort lands $4.1M in new funding
More from wrallocaltechwire.com
Market Watch
